In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Kansas

www.ctc.ku.edu

Latest From University of Kansas

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

Cleave Gains Further Validation From Investors With Addition Of $10M To Its Series A

The California biotech proves that an early-stage company can be just as attractive to investors as a proof-of-concept biotech if the science is strong.

BioPharmaceutical North America

Financings Of The Fortnight: Overseas Cash Holdings Don’t Mean U.S. Biopharma Lacks For Domestic Financial Opportunity

Plus news on recent financing activity by Savara Pharmaceuticals, OvaScience, TetraPhase Pharmaceuticals and Pharmacyclics.

BioPharmaceutical Business Strategies

Going To The Angels: Independent Investors Back $16M Series B For Savara

Savara Pharmaceuticals will finance an 80-patient Phase II trial for its inhaled vancomycin candidate as a treatment for MRSA infections in cystic fibrosis patients. Such infections have been linked with a six-year reduction in life expectancy.

BioPharmaceutical United States
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register